Legal
FTC/Actavis Ruling: Challenges and Uncertainties
While the majority opinion on FTC vs Actavis reaches an outcome that suggests pay-for-delay provisions in patent settlements are not in the best interests of the research-based industry, Tracy Medford-Rosow and Peter Richardson find the court's reasoning flawed
...Read more
Legal
FTC vs Actavis: Patent Settlements Become More Risky
In the wake of the decision on FTC vs Actavis, pharmaceutical companies can anticipate more costly, drawn-out patent litigation, writes Jill Wechsler ...Read More
Special Feature
When Management Gurus Get It Wrong
How can eminent management gurus whose strategy advice proves so valuable across
business in general sometimes get it so wrong on pharma? John Ansell provides a few
cautionary tales about stumbles involving some of the most celebrated experts ...Read more
Global
Read the New Pharm Exec Global Digest
In the new June issue: Patient adherence focus — new policy and technology initiatives from
around the globe; Japan — the country that cost containment forgot; Brazil — drug patent crisis;
Commercial model design as an enabler of growth ...Read more
Global
China Report
China is the third largest pharmaceutical market in the world and will become the second largest ahead of Japan by 2015. Everything you need to know to do business in the country; key economic sector data and exclusive interviews from regional leaders ...Read more
Video
49th Annual DIA Highlights
DIA North American Director Susan Cantrell talks about what was different about this year’s event ...Read more
|
